Cambridge biotech Mursla Bio secures £150k for AI liver cancer diagnostics

Developing blood-based tests for early liver cancer detection, Cambridge-based Mursla Bio has secured an estimated £150k in its latest funding round. Founded in 2017 as a spin-out from the University of Cambridge, the company develops diagnostic devices and non-invasive liquid biopsies to improve cancer detection and chronic disease outcomes.

The company focuses on analyzing tissue-specific extracellular vesicles (TS-EVs) from blood samples to deliver multiomic insights. Its flagship product, EvoLiver, is a blood-based test designed for early liver cancer detection in high-risk populations, such as individuals with cirrhosis. EvoLiver has received FDA Breakthrough designation for liver cancer surveillance.

This latest £150k raise (filed in May 2026) follows a series of frequent capital injections. Previous rounds include £99.9k in March 2026, £99.9k in January 2026, and £249.9k in December 2025. Throughout 2025, Mursla Bio completed multiple allotments, including £106.2k in October, £99.9k in August, and £180.6k in July. A larger round of £481.1k was recorded in December 2024.

Financial records for the year ended 31 December 2025 show Mursla Limited reported a £1.8m loss. The company currently employs between 13 and 18 staff members across its Cambridge and Boston locations.

Beyond liver cancer surveillance, Mursla Bio collaborates with pharmaceutical companies for biomarker-guided precision medicine and patient stratification. These partnerships include work in metabolic liver disease, specifically metabolic dysfunction-associated steatohepatitis (MASH). The platform is designed for expansion to other organ-specific diseases beyond its initial focus on the liver.